VaramirStart free · no cardSign in
SUPN as of Oct 31 · 20:49 ET
SUPNNasdaqPharmaceutical Preparations

Supernus Pharmaceuticals, Inc. · Brief

Next report

102 days

Feb 11 · after closeest.Q4 FY26
Earnings

Expected move

No implied move.

Implied vs realized

8 reportsHistory
0 of 6≥ implied
avg implied
±10.7%
avg realized
±2.7%
Feb 12 '26±6.1%▲+1.99%×0.33
Feb 24 '26±13.3%▲+5.67%×0.43
Q1 FY26±10.3%▲+0.20%×0.02
May 5 '26±11.8%▲+4.59%×0.39
Q2 FY26±11.3%▲+0.53%×0.05
Aug 3 '26±11.3%▲+3.07%×0.27
Oct 19 '26—▲+3.49%—
Oct 29 '26—▲+0.19%—
quarterimplied−15%0+15%realized×
Oct '26—▲+0.19%—
Oct '26—▲+3.49%—
Aug '26±11.3%▲+3.07%×0.27
Q2 FY26±11.3%▲+0.53%×0.05
May '26±11.8%▲+4.59%×0.39
Q1 FY26±10.3%▲+0.20%×0.02
2 older reports
Feb '26±13.3%▲+5.67%×0.43
Feb '26±6.1%▲+1.99%×0.33
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Feb 11 report · est.

—

Linked exposure

SUPN report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 30haltTrading halt: 19:50 ET.Source
Oct 29impliedImplied move: ±10.3% into Oct 29 earnings (Oct 29 close).Source
Oct 268-KMaterial agreement: credit line agreement with UBS Bank USA (terminated).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.